BioCryst to Present at the Eighth Annual JMP Securities Healthcare
JMP Securities Healthcare Conference 2013
RESEARCH TRIANGLE PARK, N.C. -- July 1, 2013
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives
from BioCryst are scheduled to present and provide a corporate summary and
update regarding the Company’s clinical programs at the 8^th Annual JMP
Securities Healthcare Conference in New York on Tuesday, July 9, 2013 at 3:30
p.m. Eastern Time.
Links to a live audio webcast and replay of the presentation may be accessed
on the BioCryst website events page at
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule
drugs that block key enzymes involved in infectious and inflammatory diseases,
with the goal of addressing unmet medical needs of patients and physicians.
BioCryst currently has two late-stage development programs: peramivir, a viral
neuraminidase inhibitor for the treatment of influenza, and ulodesine, a
purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout. In
addition, BioCryst has several early-stage programs: BCX4161 and a next
generation oral inhibitor of plasma kallikrein for hereditary angioedema and
BCX4430, a broad spectrum antiviral for hemorrhagic fevers. For more
information, please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including statements
regarding future results and achievements. These statements involve known and
unknown risks, uncertainties and other factors which may cause our actual
results, performance or achievements to be materially different from any
future results, performances or achievements expressed or implied by the
forward-looking statements. Please refer to the documents BioCryst files
periodically with the SEC and located at
Robert Bennett, +1-919-859-7910
Press spacebar to pause and continue. Press esc to stop.